Drug Therapy

1. Trastuzumab not for ductal carcinoma in situ?

Author
Nahleh Z; Namakydoust A; Bakkar R; Bishop J;
Institution
Karmanos Cancer Institute/Wayne State University, Detroit, Michigan ,College of Medicine, Department of Pathology, University of Cincinnati, Cincinnati, Ohio, USA.
Journal
Anticancer Drugs. 2007 Nov;18(10):1231-5.
Abstract URL
Click here to view abstract

2. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma.

Author
Jones RL; Lakhani SR; Ring AE; Ashley S; Walsh G; Smith IE;
Institution
Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK, and Molecular and Cellular Pathology, School of Medicine, University of Queensland, Mayne Medical School, Herston, Australia.
Journal
Br J Cancer. 2006 Feb 13;94(3):358-62.
Abstract URL
Click here to view abstract

3. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.

Author
Hird RB; Chang A; Cimmino V; Diehl K; Sabel M; Kleer C; Helvie M; Schott A; Young J; Hayes D; Newman L;
Institution
Division of Surgical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA.
Journal
Cancer. 2006 May 15;106(10):2113-8.
Abstract URL
Click here to view abstract

4. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma.

Author
Nakhlis F; Lazarus L; Hou N; Acharya S; Khan SA; Staradub VL; Rademaker AW; Morrow M; Nakhlis F; Lazarus L; Hou N; Acharya S; Khan SA; Staradub VL; Rademaker AW; Morrow M;
Institution
Department of Surgery, Lynn Sage Breast Program, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Journal
J Am Coll Surg. 2005 Nov;201(5):688-94. Epub 2005 Aug 31.
Abstract URL
Click here to view abstract